Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2101 to 2115 of 8910 results

  1. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]

    In development Reference number: GID-TA11764 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development

  2. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 23 February 2026.

    NICE guideline
    In consultation

  3. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development Reference number: GID-NG10216 Expected publication date:  15 July 2026

    NICE guideline
    In development

  4. Lifileucel for previously treated unresectable or metastatic melanoma ID3863

    In development Reference number: GID-TA10752 Expected publication date:  10 July 2026

    Technology appraisal guidance
    In development

  5. AHEAD implants for external ear prosthesis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  6. Intradiscal oxygen-ozone treatment of symptomatic lumbar disc herniation

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  7. Insertion of Stoma Preservation Device

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  8. Botulinum Toxin injection prior to Abdominal wall reconstruction

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  9. Olorofim for treating invasive fungal infections in people 16 years and over [TSID11983]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Secukinumab biosimilar for treating plaque psoriasis [TSID11992]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears [TSID8472]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [TSID11969]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Golimumab for treating moderately to severely active ulcerative colitis in people aged 2 to 17 years [TSID11959]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Apremilast for treating moderate to severe plaque psoriasis in people aged 6 to 17 [TSID11921]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation